anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other insulin glargine products may be misleading.

All insulin products can elicit the formation of insulin antibodies. The presence of such insulin antibodies may increase or decrease the efficacy of insulin and may require adjustment of the insulin dose. In clinical studies of insulin glargine, increases in titers of antibodies to insulin were observed in NPH insulin and insulin glargine treatment groups with similar incidences.
Prostate cancer (PC) is an entity that encompasses different types of tumors, including adenocarcinomas and non-adenocarcinomas. Adenocarcinomas and non-adenocarcinomas respond to, and therefore should be treated, with different treatments. Even within the adenocarcinomas, the lethality of tumors is highly variable, from low risk/indolent/non-life threatening to high risk/lethal. The inability to accurately predict the behavior of a particular cancer makes treatment decisions difficult and highly inexact. Elevated expression of prostate specific membrane antigen (PSMA) expression is a molecular hallmark of lethal prostate adenocarcinoma. Assessment of PSMA expression levels to predict the behavior of a particular cancer will be useful in the diagnosis and treatment of PC.
NEW MATERIAL:An antibiotic TAN-868A of the formula or its salt. USE:Medicine. A remedy for bacterial infections in mammarians or bactericidal. It is active against gram-positive, gram-negative and acid-fast bacteria containing resistant strains and fungi. The dose is 1-25mg/kg/day in subcutaneous and intravenous application, while as an antiseptic, it is dissolved in distilled water in a concentration of 0.01-0.1W/V% and the solution is applied to hands, feet, eyes or ears of mammarians. PREPARATION:A microorganism in Streptomyces, which has germ tube or mycelium-like projections on the side surface of the spores which are formed in chains on the top of aerial hyphae and is capable of producing an antibiotic TAN-868A such as Streptomyces idiomorfus is cultured in a medium to allow the bitotic to accumulate in the culture mixture. Then, the substance is collected to obtain the antibiotic or its salt.
The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
BACKGROUND: Rotavirus infections are a significant cause of severe diarrhea and related illness and death in children under five worldwide. Despite the global introduction of vaccinations for rotavirus over a decade ago, rotavirus infections still result in high deaths annually, mainly in low-income countries, including Ethiopia, and need special attention. This system review and meta-analysis aimed to comprehensively explore the positive proportion of rotavirus at pre- and post-vaccine introduction periods and genotype distribution in children under five with diarrhea in Ethiopia.
METHODS: The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Database sources included PubMed, Scopus, EMBASE, and Epistemonikos, focusing on studies published before November 30, 2023. The search targeted rotavirus infection and genotype distribution in Ethiopia before and after the introduction of the Rota vaccine. Data was managed using EndNote 2020 software and stored in an Excel 2010 sheet. A random-effects model determined the pooled estimate of the rotavirus infection rate at 95% confidence intervals. The Q-and I² statistics were used to assess the study heterogeneity, and a funnel plot (Egger test) was used to determine the possibility of publication bias.
RESULTS: The analysis included data from nine studies conducted in different regions of Ethiopia. The overall prevalence of rotavirus infection was significant, with a prevalence rate of approximately 22.63% (1362/6039). The most common genotypes identified before the Rota vacation introduction were G1, G2, G3, G12, P [4], P [6], P [8], P [9], and P [10]. Meanwhile, G3 and P [8] genotypes were particularly prevalent after the Rota vaccine introduction. These findings highlight the importance of implementing preventive measures, such as vaccination, to reduce the burden of rotavirus infection in this population. The identified genotypes provide valuable insights for vaccine development and targeted interventions.
CONCLUSION: This study contributes to the evidence base for public health interventions and strategies to reduce the impact of rotavirus infection in children under five in Ethiopia. Despite the rollout of the Rota vaccination in Ethiopia, rotavirus heterogeneity is still high, and thus, enhancing vaccination and immunization is essential.
Icatibant injection is supplied as a single-dose, prefilled syringe for subcutaneous administration. Each syringe delivers 3 mL of a sterile solution of icatibant 30 mg (as icatibant acetate). Each glass syringe has a bromobutyl plunger stopper, which is not made of latex natural rubber. 

Icatibant injection is available in cartons containing one single-dose, prefilled syringe and one 25 G Luer lock needle. NDC 69097-664-34. 

Icatibant injection is also available in a pack containing 3 cartons; each carton contains one single-dose, prefilled syringe and one 25 G Luer lock needle. NDC 69097-664-68.
Placebo: organic brown rice The dosage of Placebo is 8 capsules three times a day for 4 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary. Should swallowing capsules be an issue, they can be opened and dispensed into water or juice for easy ingestion.
Participants will undertake a back school-based program. This program will follow the recommendations of the biopsychosocial model of chronic pain and will be conducted in an aquatic environment. The intervention will be carried out by physiotherapists in a sports center. The duration of the intervention will be six weeks, with a frequency of two sessions per week, totaling 12 sessions of 45 minutes each. Of all the sessions, 10 will have a practical focus (centered on trunk exercises) and the other two will have a theoretical focus (providing education on pain and risk factors for low back pain).
PROBLEM TO BE SOLVED: To evaluate and discriminate effects of a skin preparation for external use such as a cosmetic on skin by using a change in coordinate positions prior to and after the use. SOLUTION: A change in coordinates in a space comprising two axes of an axis of skin color and an axis of skin transparency is used as an index. The Munsell color coordinates are preferably used as the axis indicating the color and its hue is preferably used. The axis to which skin color belongs is YR and the numerical value of the YR can be used as the axis of the color. The maximum value (Max-Rao) of a ratio of differences in reflectances at each wavelength is preferably calculated by irradiating the skin with visible light from two directions and measuring the respective optical spectra of each reflected light for use as the axis of the skin transparency.  In the prepared coordinates using the skin color and the skin transparency as the axes, a change in plotted positions prior to and after use of a skin preparation for external use can be used as an index to discriminate and evaluate effects of the use of the skin preparation for external use. Thereby, the skin preparation for external use can be evaluated and discriminated.
Participants in this group received visual perceptual training based on the lateral masking paradigm every other day for 35 to 45 minutes, with each cycle consisting of 40 sessions, lasting approximately 3 months. The training began in the hospital during the first week and continued at home using personal computers thereafter. The personal computers were connected to a central server via the internet.
The invention relates to pH-responsive binary supramolecular nanoparticles. The construction unit uses sulfonated cyclodextrin as a host and chitosan as a guest, thereby constructing the supramolecular assembly under the host-guest electrostatic interactions. The preparation method comprises the following steps: dissolving the sulfonated cyclodextrin and chitosan in water, and uniformly mixing to obtain a binary supramolecular nanoparticle solution. As the pH value of the solution is gradually regulated to alkality, the assembly nanoparticles gradually are depolymerized; as the pH value of the solution is gradually regulated to acidity, the nanoparticles reform; the assembly nanoparticles have favorable circulating property for pH response; and the binary supramolecular nanoparticles are used for carrying trisodium 8-hydroxypyreny-1,3,6-trisulfonate. The preparation method of the nano supramolecular nanoparticles is simple and convenient. The prepared supramolecular nanoparticles have the advantages of favorable biocompatibility, favorable stability and favorable selection responsivity for pH, and create favorable conditions for specific carried drugs for treating diseases and the like.
INTRODUCTION: Chronic obstructive pulmonary disease (COPD)/obstructive sleep apnoea (OSA) overlap syndrome (OVS) is associated with higher mortality compared with COPD alone in stable outpatients. However, the prognosis of patients hospitalised with acute hypercapnic respiratory failure (ARF) is unclear.
METHODS: In this retrospective cohort study, 124 patients with COPD and 44 patients with OVS were treated with positive airway pressure (PAP) for ARF and followed up for a median of 20.6 months (IQR 3.80-53.4). Patients treated in the emergency or intensive care units and did not continue PAP on the wards were excluded. We compared patient characteristics and overall survival.
RESULTS: Mean (SD) age of participants was 71 (9.7) years and 51% were males. Patients with OVS had a higher prevalence of hypertension (75% vs 50.0%, p=0.004) and type 2 diabetes mellitus (45.5% vs 19.4%, p<0.001). There was no difference in arterial pH or carbon dioxide levels at presentation. On univariate analysis, mortality was lower in OVS compared with patients with COPD alone (HR 0.57, 95% CI 0.37 to 0.87). Median survival was 51.0 (95% CI 38.1 to 93.7) months in OVS and 27.7 (95% CI 16.9 to 35.1) months in COPD alone. Median survival in OVS prescribed home PAP therapy was significantly higher (59.0 months) compared with OVS not discharged on therapy (36.1 months), and to patients with COPD, irrespective of home therapy prescription (p=0.022). After adjusting for multiple known confounders, patients with OVS still appeared to have lower mortality; however, this was no longer statistically significant (HR 0.75, 95% CI 0.45 to 1.24).
DISCUSSION: We found that patients with COPD and ARF requiring non-invasive ventilation may have higher mortality rates compared with patients with OVS. Patients with OVS treated with home PAP had lower mortality compared with patients not prescribed PAP on discharge. These findings suggest that patients with COPD who present with ARF may benefit from early diagnosis of OSA and initiation of long-term PAP therapy.
INTRODUCTION: The scarcity of suitable donor organs has led to the inclusion of Expanded Criteria Donor (ECD) kidneys to augment the donor pool, despite potential concerns regarding post-transplant outcomes.
METHODS: This retrospective study analyzed the clinical outcomes of a cohort of 317 kidney transplant recipients from deceased donors at a single center between 2008 and 2018. Patients were categorized into ECD and Standard Criteria Donor (SCD) groups, with primary nonfunctioning grafts excluded. Comprehensive laboratory evaluations were conducted, including HLA typing and serum creatinine levels. Immunosuppressive regimens were standardized, and statistical analyses were performed using the SPSS program.
RESULTS: The sample consisted of 83 (26.18%) patients who received kidney transplants from ECDs and 234 (73.82%) from SCDs. The ECD group showed a longer cold ischemia time (p = 0.019) and a higher rate of delayed graft function (DGF) compared with the SCD group. No significant differences were observed in graft survival (p = 0.370) or patient survival (p = 0.993) between the ECD and SCD groups. However, differences in graft survival were noted between the groups when stratified by DGF status: ECD with DGF vs. ECD without DGF (p = 0.029), ECD with DGF vs. SCD with DGF (p = 0.188), ECD with DGF vs. SCD without DGF (p = 0.022), ECD without DGF vs. SCD with DGF (p = 0.014), ECD without DGF vs. SCD without DGF (p = 0.340), and SCD with DGF vs. SCD without DGF (p = 0.195). No differences in patient survival rates were observed among these groups for all pairwise comparisons (p > 0.05) when stratified by donor criteria and DGF status.
CONCLUSIONS: Graft and patient survival rates were comparable between ECD and SCD kidney transplant recipients.
Additionally to standard of care, measurements for donor-derived cell-free DNA (dd-cfDNA) are performed at months 0, 1, 3, 6, 9, and 12. These measurements are not used to guide kidney allograft biopsies. Those are performed according to standard of care as determined by the treating physicians.
The invention relates to a medicine for detoxification and sores removal, in particular to a medicine for detoxification and masses resolving. The invention aims to provide a medicine for detoxificationand sores removal, diseases elimination of postulation and multi-place sores and  masses resolving. The medicine for detoxification and masses resolving comprises sulfur, perch sand, aconite, realgar, chinese trumpetcreeper, earthworms, dried silkworms, scorpion, sclerotium mylittae, radix sileris and cedar seeds, wherein the aconite is raw aconite; the chinese trumpetcreeper is trumpet creeper; the earthworms are roasted earthworms; and the dried silkworms and the scorpion are fried dried silkworms and fried scorpion. The sulfur, the perch sand, the aconite and the realgar are rammed into powder; and the power is mixed with bitter liquor into slurry to be applied to the affected part. The chinese trumpetcreeper, the earthworms, the dried silkworms, the scorpion, the sclerotium mylittae, the radix sileris and the cedar seeds are prepared into powder; and 6 grams are taken orally with wine each time. By adoption of the medicine, toxicum and the sores can be removed and diseases of postulation and multi-place sores can be eliminated.
PURPOSE: To obtain a compd. which suppresses the formation of side products and is useful for treating benign prostatic hypertrophy(BPH) by allowing hexamethyldisilazane to exist at the time of reaction of Δ 1 -azaester with Grignard reagent.  
     CONSTITUTION: The compd. of formula I and a Grignard reagent of the formula RMgX (R is a 3 to 10C alkyl; X is I, Br, Cl) are brought into contact for a sufficient time in the presence of the hexamethyldisilazane(HMDS) at a temp. of -5 to 65°C in an anhydrous inert org. solvent (more adequately THF, etc.), by which the objective compd. of formula II is obtd. The reaction is recommended to be executed generally by adding Mg to the anhydrous solvent at a room temp. under an inert atmosphere, then adding 3 to 10C alkyl halide thereto to form the Grignard reagent, mixing the reagent, under stirring, with a suspension in which the compd. of the formula I and the hexamethyldisilazane are suspended, then stirring the resulted soln. for 1 to 2 hours at room temps. in an inert atmosphere and heating and refluxing the soln. for 10 to 12 hours. 
     COPYRIGHT: (C)1992,JPO
<P>PROBLEM TO BE SOLVED: To provide a new strain effective for preventing and/or treating infections with enterohemorrhagic Escherichia coli, a pharmaceutical composition containing the strain, a fermentation product, a food and a method for preventing and/or treating infections with enterohemorrhagic Escherichia coli.  <P>SOLUTION: The Bifidobacterium infantis 157F strain is newly found. The pharmaceutical composition contains Bifidobacterium infantis 157F strain. The fermentation product and the food are provided. The method for preventing and/or treating infections with enterohemorrhagic Escherichia coli includes using Bifidobacterium infantis 157F strain.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The primary objective of this investigation is to determine the impact of oxytocin (OT), a peptide hormone that influences social affiliation, on socioemotional neural circuitry and eating disorder behavior in anorexia nervosa (AN). Because socioemotional processing deficits appear to play a key role in AN, OT is implicated as a potential biological mechanism by which eating disorder behavior (e.g., restrictive eating) is maintained. Used as a probe, intranasal oxytocin (INOT) provides an innovative method for examining the short-term impact of OT on socioemotional neural processing disturbances and eating disorder behavior in AN. The proposed study tests a theoretical model of the role of OT in the maintenance of AN by using an INOT probe to determine, and potentially alter, neurobiological responses to socioemotional stimuli. Specifically, this study will use a randomized, controlled, double-blind design involving the administration of INOT or placebo to adults with AN restricting subtype and age-matched controls prior to neuroimaging to assess the impact on frontolimbic brain activity in response to socioemotional stimuli. The potential impact of INOT on restrictive eating will also be assessed in a subsequent test meal. We predict that for participants with AN, INOT, but not placebo, will normalize frontolimbic activation in response to social reward stimuli and prefrontal activation in response to social threat stimuli. In addition, the investigators predict that AN participants will display reduced restrictive eating in a test meal paradigm following INOT (but not placebo) administration. Finally, investigators predict that changes in restrictive eating following INOT administration will be mediated by altered frontolimbic responding to socioemotional cues. This investigation will provide an essential link uniting the data supporting the importance of socioemotional processing deficits in AN with the emerging role of INOT in altering the neural circuits involved in social behavior to test an innovative neurobiological maintenance model of AN.
Spinal Mobilization with Leg Movement (SMWLM) will be given as intervention to experimental group. Participants will be given Hot pack for 15 minutes, TENS for 10 minutes.
Elderly patients may suffer from asymptomatic renal and hepatic dysfunction. Care should be taken when administering PREVPAC to this patient population.

An analysis of clinical studies of amoxicillin was conducted to determine whether subjects aged 65 and over respond differently from younger subjects. Of the 1,811 subjects treated with capsules of amoxicillin, 85% were less than 60 years old, 15% were ≥ 61 years old and 7% were ≥ 71 years old. This analysis and other reported clinical experience have not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

In a steady-state study in which healthy elderly subjects (age 65 to 81 years old) were given 500 mg every 12 hours, the maximum serum concentrations and area under the curves of clarithromycin and 14-OH clarithromycin were increased compared to those achieved in healthy young adults. These changes in pharmacokinetics parallel known age-related decreases in renal function. In clinical trials, elderly patients did not have an increased incidence of adverse events when compared to younger patients. Dosage adjustment should be considered in elderly patients with severe renal impairment (see WARNINGS and PRECAUTIONS).
PURPOSE: Valbenazine is commonly used to treat tardive dyskinesia, and we conducted a pharmacovigilance analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS) to evaluate neurological safety signals associated with valbenazine.
METHODS: Data was collected in FAERS from the second quarter of 2017 to the fourth quarter of 2023 for data cleaning. Neurological adverse event (AE) signals of valbenazine were mined by calculating reporting odds ratios (ROR), information component (IC) and empirical Bayesian geometric mean (EBGM). The serious and non-serious cases and signals were prioritized using a rating scale.
RESULTS: The number of neurological AE reports where the primary suspect (PS) drug was 8981 for valbenazine. Significant AE signals were identified by the preferred term (PT) analysis for valbenazine, including somnolence (ROR 19.69), tremor (ROR 15.17), and tardive dyskinesia (ROR 236.91), among which 18 AEs were identified as new signals. Patient age (p < 0.009) and sex (p = 0.197) might be associated with an increased risk of neurological AE severity. Notably, the association between valbenazine and neurological disorders remained when stratified by sex, age, and reporter type. AE timing analysis was performed for the drug and four moderate clinical priority signals [i.e., somnolence, balance disorder, parkinsonism, and akathisia (priorities 7)], showing the same early failure type profiles.
CONCLUSIONS: The increase in neurological safety signals is identified in the post-marketing research of valbenazine. Clinicians need to pay attention to not only common AEs but also be alert to new neurological AE signals when using valbenazine.
OBJECTIVE: High-risk human papillomavirus (hrHPV) testing using dry-type self-sampled vaginal specimens is becoming more widespread worldwide due to increased screening uptake. However, for the triage of hrHPV-positive women, a visit to a general practitioner is required for reflex cytology. This study aimed to evaluate the hrHPV detection capability of CellSoft®, a wet-type self-sampling method that also allows for cytology.
METHODS: Thirty-eight women aged 20 years and older were included in the study. The women self-sampled using CellSoft® after using an Evalyn® Brush. PCR-based HPV genotyping was performed on both specimens and hrHPV detection results of both devices were compared. Additionally, cytological exam was performed on CellSoft® samples.
RESULTS: Overall agreement between self-sampling devices for the detection of hrHPV in CellSoft® and Evalyn Brush was observed in 97.4% (37/38) of participants. More hrHPV genotypes were detected with Evalyn Brush than with CellSoft®. Among the 22 CellSoft® hrHPV-positive cases, 11 (47.6%) were atypical squamous cells of undetermined significance or worse.
CONCLUSION: CellSoft® hrHPV genotype detection results were in good agreement with those of Evalyn Brush. CellSoft® provided a sufficient cell volume for HPV testing and cytological evaluation.